User:Mr. Ibrahem/Denosumab
 Denosumab injection | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | RANK ligand |
| Clinical data | |
| Trade names | Prolia, Xgeva |
| Other names | AMG-162 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610023 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| Drug class | RANKL inhibitor[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Metabolism | proteolysis |
| Chemical and physical data | |
| Formula | C6404H9912N1724O2004S50 |
| Molar mass | 144722.80 g·mol−1 |
  (what is this?) (verify) | |
Denosumab, sold under the brand names Prolia and Xgeva, is used to treat osteoporosis, bone cancer, and high calcium due to cancer.[2] It is given by injection under the skin.[2] It is used with calcium supplements and vitamin D.[3]
Common side effects include joint and muscle pain.[1] Other side effects may include cellulitis, low calcium, allergic reactions, and osteonecrosis of the jaw.[1] It is a monoclonal antibody that attaches to and inhibits RANKL, which decreases osteoclasts breaking down bone.[1]
Denosumab was approved for medical use in the United States and Europe in 2010.[2][1] In the United Kingdom 60 mg cost the NHS about £180 as of 2021.[3] In the United States this amount costs about 1,250 USD.[4]
References
[edit]- ^ a b c d e f "Prolia". Archived from the original on 16 September 2021. Retrieved 23 December 2021.
- ^ a b c d "Denosumab Monograph for Professionals". Drugs.com. Archived from the original on 30 April 2021. Retrieved 23 December 2021.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 776. ISBN 978-0857114105.
- ^ "Prolia Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 8 October 2021. Retrieved 23 December 2021.